ID | 62810 |
JaLCDOI | |
フルテキストURL | |
著者 |
Iwata, Takehiro
Department of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
Kaken ID
Maruyama, Yuki
Department of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
Kawada, Tatsushi
Department of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
Sadahira, Takuya
Department of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
Katayama, Satoshi
Department of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
Takamoto, Atsushi
Department of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
Sako, Tomoko
Department of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
Wada, Koichiro
Department of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
ORCID
researchmap
Edamura, Kohei
Department of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
Kobayashi, Yasuyuki
Department of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
ORCID
Kaken ID
Araki, Motoo
Department of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
ORCID
Kaken ID
publons
researchmap
Watanabe, Masami
Department of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
Kaken ID
publons
researchmap
Watanabe, Toyohiko
Department of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
ORCID
Kaken ID
publons
researchmap
Nasu, Yasutomo
Department of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
Kaken ID
publons
researchmap
|
抄録 | Optimal neoadjuvant hormone therapy (NHT) for reducing prostate cancer (PC) patients’ prostate volume pre-brachytherapy is controversial. We evaluated the differential impact of neoadjuvant gonadotropin-releasing hormone (GnRH) antagonist versus agonist on post-brachytherapy testosterone recovery in 112 patients treated pre-brachytherapy with NHT (GnRH antagonist, n=32; GnRH agonists, n=80) (Jan. 2007-June 2019). We assessed the effects of patient characteristics and a GnRH analogue on testosterone recovery with logistic regression and a propensity score analysis (PSA). There was no significant difference in the rate of testosterone recovery to normal levels (> 300 ng/dL) between the GnRH antagonist and agonists (p=0.07). The GnRH agonists induced a significantly more rapid testosterone recovery rate at 3 months post-brachytherapy versus the GnRH antagonist (p<0.0001); there was no difference in testosterone recovery at 12 months between the GnRH antagonist/agonists (p=0.8). In the multivariate analysis, no actor was associated with testosterone recovery. In the PSA, older age and higher body mass index (BMI) were significantly associated with longer testosterone recovery. Post-brachytherapy testosterone recovery was quicker with the neoadjuvant GnRH agonists than the antagonist, and the testosterone recovery rate was significantly associated with older age and higher BMI. Long-term follow-ups are needed to determine any differential effects of GnRH analogues on the quality of life of brachytherapy-treated PC patients.
|
キーワード | testosterone recovery
GnRH antagonist
GnRH agonist
brachytherapy
prostate cancer
|
Amo Type | Original Article
|
出版物タイトル |
Acta Medica Okayama
|
発行日 | 2021-12
|
巻 | 75巻
|
号 | 6号
|
出版者 | Okayama University Medical School
|
開始ページ | 705
|
終了ページ | 711
|
ISSN | 0386-300X
|
NCID | AA00508441
|
資料タイプ |
学術雑誌論文
|
言語 |
英語
|
著作権者 | Copyright Ⓒ 2021 by Okayama University Medical School
|
論文のバージョン | publisher
|
査読 |
有り
|
PubMed ID | |
Web of Science KeyUT | |
NAID |